The treatment of cancer is a rapidly evolving field. As more chemotherapeutic agents become available, reporting the side effects of these agents in clinical practice becomes increasingly important. Nivolumab is one of the chemotherapeutic agents commonly used for treatment of renal cell carcinoma, metastatic melanoma, and metastatic non-small cell lung cancer. While common side effects are known and well documented, encephalitis is documented as an extremely rare side effect. We present the case of an extremely rare side effect to a common chemotherapeutic agent.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2mO9GQg
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Abstract Objective The objective of this study were to find the annual case trend of inflammatory jawbone diseases and to investigate th...
-
The investigational third-generation nonsteroidal oral selective estrogen receptor degrader RAD1901 was associated with a 23% objective resp...
-
by Patrick P. Lowe, Benedek Gyongyosi, Abhishek Satishchandran, Arvin Iracheta-Vellve, Aditya Ambade, Yeonhee Cho, Karen Kodys, Donna Catala...
-
The new app from IBM will let crowds automatically coordinates mass displays at big sporting events or protests using their smartphone camer...
-
A magnetic Fe3O4/GO composite with potential for rapid solid-liquid separation through a magnetic field was synthesized using GO (graphene o...
-
Medicaid is slated to lose billions of dollars in funding, as are many medical, humanitarian and scientific organisations from #Alexandro...
-
Abstract Glutamine (GLUT) is a nonessential amino acid that can become conditionally essential under stress conditions, being able to act ...
-
Norges første retningslinje for rehabilitering av pasienter med ervervet overekstremitetsamputasjon er nå tilgjengelig på nett. Retningslin...
-
A new beginning Anirudh Kohli Indian Journal of Radiology and Imaging 2019 29(1):1-1 Is next-generation radiologist ready for the challenges...
-
Vol.68 No.1 from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2iwPjTH via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου